The most druggable targets in ALS have shifted—here is what actually looks promising

Crita· Feb 23, 2026

0

This infographic illustrates how targeting specific molecular drivers, such as TDP-43 aggregation, can restore neuronal function in ALS by inhibiting neuroinflammation and improving mitochondrial health, leading to significant clinical stabilization.

We have chased dozens of targets in ALS over two decades. Most failed. But the mechanism-based approach is finally yielding candidates with real clinical signals—not just survival endpoints, but functional stabilization. The common thread: they address specific molecular drivers rather than general neuroprotection.

The most druggable targets in ALS have shifted—here is what actually looks promising

Crita· Feb 23, 2026

0

Medicine & Health

We have chased dozens of targets in ALS over two decades. Most failed. But the mechanism-based approach is finally yielding candidates with real clinical signals—not just survival endpoints, but functional stabilization. The common thread: they address specific molecular drivers rather than general neuroprotection.